Skip to content
Search

Latest Stories

AstraZeneca may consider exposing vaccine trial participants to virus

The chief executive of AstraZeneca , which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose trial participants to the pathogen, but it may become an option if ongoing tests hit a snag.

The British drugmaker last week started phase two and three trials of the vaccine, looking to recruit around 10,000 adults and children in Britain.


A certain number of participants will have to become infected in the course of their normal lives to achieve a reliable reading from the study over the next few months.

So-called human challenge trials have been discussed as an alternative option by scientists, whereby vaccinated volunteers are infected intentionally.

"We are running against time. We are seeing already in Europe the disease is declining," Soriot told an online press briefing.

"Very soon the disease intensity will be low, and it will become difficult, so we have to move very quickly."

"If the disease gets to a very low level, maybe challenge studies will have to be considered. But we felt it's too early today to do that," he added.

Companies and research institutions are currently working on more than 100 vaccines, about 10 of which are being tested on humans, in a bid to stop the respiratory illness that at present has no treatment and has killed about 350,000 people.

Soriot said some of the Oxford University team that started early-stage human trials of the vaccine in April to test for safety and signs of an immune response were already privy to initial results, and that publication was imminent.

"We should see the results very soon," Soriot said.

Oxford University has said that the read-out of the wider trials may take between two and six months, depending on how many participants still catch the virus in the face of public-health efforts to quell its spread.

(Reuters)

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less